• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nightingale Health

0.85 EUR

-3.20 %

4,730 following

HEALTH

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Investor consensus
Compare
-3.20 %
-14.37 %
-41.33 %
-58.73 %
-60.65 %
-66.63 %
-6.52 %
-83.57 %
-83.57 %

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more
Market cap
51.55M EUR
Turnover
126.5K EUR
P/E (adj.) (26e)
-2.95
EV/EBIT (adj.) (26e)
-0.65
P/B (26e)
1
EV/S (26e)
1.96
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
1.40 EUR
Updated
11.06.2026
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 12.06.2026

Latest extensive report

Released: 13.06.2025

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Here are Antti’s comments on Nightingale’s profit warning. Inderes – 9 Jun 26 Nightingalen tulosvaroitus: Projektiviivästys siirtää liikevaihtoa ensi... Yhtiön liiketoiminta näyttää etenevän ennusteidemme mukaisesti.
6/9/2026, 5:19 AM
by Sijoittaja-alokas
13
Highlights from the article published by the University of Eastern Finland on May 28: "Demonstrating the effectiveness of preventive healthcare has traditionally required long follow-up studies spanning several years because diseases develop slowly. NMR metabolomics (NMR-metabolomiikka...
6/2/2026, 2:46 PM
by The Ugly Buckling
13
Inderes Nightingale: Huomioimme projektin siirtymisen ennusteissamme - Inderes Seuraavan tilikauden liikevaihtonäkymä ylittää 10 MEUR.
6/12/2026, 5:39 AM
by Pertti
12
I’ll argue against that a bit: an analyst must assume these deals and the progress of projects behind their forecasts if they expect revenue growth. What else would the assumption of growth be built on? Then, the news flow provides one clear data point on the validity of these assumptions...
6/4/2026, 6:54 AM
by Antti Luiro
10
Profit warning. The project is delayed but will be completed, says Suna. Inderes Sisäpiiritieto, tulosvaroitus: Nightingale Health jatkaa kasvuaan mutta ei... Nightingale Health Oyj | Sisäpiiritieto | 08.06.2026 klo 19:25:00 EESTNightingale Health (Nasdaq Helsinki: HEALTH; OTCQX:...
6/8/2026, 5:19 PM
by TZ
9
Here is a new company report on Nightingale from Antti & Antti at Inderes following the latest news During the beginning of the year, Nightingale has announced three new projects or partnerships. In our assessment, these new ventures are pilot-type projects, and their potential commercial...
6/4/2026, 5:12 AM
by Sijoittaja-alokas
9
In addition to that target price of €1.4, Antti’s analysis mentioned a wider range of €0.5–€5; in that sense, the difficulty of determining the valuation for this type of stock was acknowledged.
6/4/2026, 7:04 AM
by J
6
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
16.9
2026

Annual report '26

5.11
2026

General meeting '26

9.3
2027

Interim report Q2'27

Nightingale: We factored the project delay into our estimates
Research6/12/2026, 7:20 AM by
Antti Siltanen, Antti Luiro

Nightingale: We factored the project delay into our estimates

The revenue outlook for the next fiscal year exceeds 10 MEUR.

Nightingale Health
Nightingale's profit warning: Project delay shifts revenue to next year
Analyst Comment6/9/2026, 6:40 AM by
Antti Siltanen

Nightingale's profit warning: Project delay shifts revenue to next year

The company's business appears to be progressing in line with our estimates.

Nightingale Health
Regulatory press release6/8/2026, 4:25 PM

Inside information, profit warning: Nightingale Health continues to grow but will not reach its 50% growth target this financial year as about EUR 2 million of revenue shifts to next financial year

Nightingale Health

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Nightingale: Nightingale sings to a deaf market
Research6/4/2026, 6:36 AM by
Antti Siltanen

Nightingale: Nightingale sings to a deaf market

The low valuation compensates for the very high level of risk.

Nightingale Health
Nightingale joins wellbeing services county research project
Analyst Comment5/29/2026, 6:46 AM by
Antti Siltanen

Nightingale joins wellbeing services county research project

Nightingale's risk screening selects participants for lifestyle coaching.

Nightingale Health
Press release5/28/2026, 8:00 AM

Nightingale Health joins South Savo Wellbeing Services County's preventive healthcare research project in Finland

Nightingale Health
Regulatory press release5/27/2026, 1:45 PM

Nightingale Health Plc’s financial reporting and Annual General Meeting in financial year 2026–2027

Nightingale Health
New partnership for Nightingale
Analyst Comment5/25/2026, 6:11 AM by
Antti Siltanen

New partnership for Nightingale

The new memorandum of understanding will expand blood analysis to the longevity programs in Switzerland and South Africa as early as this summer.

Nightingale Health
Press release5/22/2026, 6:30 AM

Nightingale Health and Formula 100 Health partner in preventive health: Embedding multi-disease risk detection across longevity programmes in Switzerland and South Africa

Nightingale Health
Regulatory press release5/21/2026, 2:25 PM

Nightingale Health Plc – Managers’ Transactions – Olli Karhi

Nightingale Health
Regulatory press release5/18/2026, 10:02 AM

Nightingale Health Plc: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act (Cor Group Oy)

Nightingale Health
US market roadmap for medical devices – a European perspective
Analyst Comment3/27/2026, 10:45 AM by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit
Nightingale H1'26: Research projects accelerate H2
Research3/6/2026, 9:44 AM by
Antti Siltanen

Nightingale H1'26: Research projects accelerate H2

Nightingale's major research projects will generate revenue in H2.

Nightingale Health
Nightingale, Webcast, Half-year financial report 1 July–31 December 2025
Webcast3/5/2026, 12:00 PM

Nightingale, Webcast, Half-year financial report 1 July–31 December 2025

Nightingale Health
Regulatory press release3/5/2026, 7:00 AM

Nightingale Health's half-year report: Delivering clinical value for healthcare and moving toward 50% revenue growth, supported by a strong sales pipeline

Nightingale Health
Nightingale H1'26 preview: Revenue still relies on research projects
Analyst Comment3/3/2026, 7:11 AM by
Antti Siltanen

Nightingale H1'26 preview: Revenue still relies on research projects

We expect revenue to grow, driven by research projects and the Terveystalo collaboration.

Nightingale Health
A step forward for Nightingale in New York
Analyst Comment2/10/2026, 6:50 AM by
Antti Siltanen

A step forward for Nightingale in New York

The New York laboratory permit allows tests to be offered to healthcare providers without separate FDA approval.

Nightingale Health
Regulatory press release2/9/2026, 7:30 PM

Inside information: Nightingale Health achieves major milestone in the United States: New York laboratory now holds a clinical laboratory permit from New York State

Nightingale Health
Another welfare services country is piloting Nightingale's technology
Analyst Comment12/18/2025, 5:54 PM by
Antti Luiro, Antti Siltanen

Another welfare services country is piloting Nightingale's technology

The North Karelia wellbeing services county is piloting Nightingale's blood analysis technology.

Nightingale Health
Press release12/18/2025, 1:00 PM

North Karelia Wellbeing Services County adopts Nightingale Health’s disease risk assessment as part of public healthcare in Finland

Nightingale Health